The Art of Living Revives Radha Kunj Lake: A Testament to Environmental Health
Water pollution poses a significant threat to environmental and human health, with various sources such as residential, industrial, agricultural, and livestock activities contributing to its degradation. Traditional methodologies for addressing water pollution often fall short, necessitating innovative solutions. Nature based interventions have emerged as effective strategies for mitigating water pollution, leveraging the inherent power of natural elements like microorganisms, plants, and algae. Says Gurudev Sri Sri Ravi Shankar, \"We need to protect the environment- this is our first and foremost duty as citizens of this world. If we take care of the environment, it will take care of us and bring us health, prosperity, and happiness.''
"); document.write("Amidst the tranquil landscape of The Art of Living International Centre in Bengaluru, lies Radha Kunj Lake, also known as Udipalya Kere, once faced with severe pollution issues, endangering aquatic life, and posing health risks to the surrounding ecosystem. To combat this challenge, a multi-faceted approach incorporating nature-based solutions was implemented in April 2023 by The Art of Living. Boulder checks were strategically installed along the stream to filter pollutants and facilitate natural filtration processes. Additionally, native vegetation and hyperaccumulator plants were reintroduced to absorb contaminants and restore ecological balance.
"); document.write("Microbial remediation techniques, such as bioremediation and phycoremediation, played a crucial role in detoxifying the water. Bio-bridges constructed with indigenous materials provided habitats for microbial communities, while diatomaceous algae were introduced to enhance the lake's natural cleansing abilities. Furthermore, aeration through fountain systems injected oxygen into the water, revitalising the aquatic habitat and promoting biodiversity.
L-Nutra, the premier nutri-technology company, has unveiled the results of a pioneering clinical trial, published in Diabetologia, which aims to redefine the approach to managing Type 2 Diabetes. Conducted over a 12-month period and compared to the current standard of care, the study assessed the impact of a Fasting Mimicking Diet (FMD) on glycemic control and medication reduction, delivering compelling evidence to support the integration of the FMD program into primary care management of Type 2 Diabetes.
"); document.write("Over 30 million people in the U.S. suffer from diabetes, and nearly 98 million have pre-diabetes. These striking numbers directly correlate with unhealthy lifestyles and medications that mostly slow disease progression rather than reversing it. This new data suggests a viable, nutrition-led intervention that enhances the effectiveness of the standard of care, allowing the possibility of diabetes regression to be within reach.
"); document.write("The research involved 100 Type 2 Diabetes patients with a BMI greater than 27 and HbA1C levels above 6.5%, who were either on standard care or treated with Metformin. This randomized, controlled, assessor-blinded trial introduces a new paradigm in diabetes management, focusing on \"glycemic management,'' a new metric used to measure efficacy by medication reduction.
Researchers Discover Novel Drug Candidate to Combat Fatty Liver Disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a burgeoning global health concern, posing a significant threat to public health and escalating the burden on healthcare resources. Characterized by the accumulation of fat in the liver, MASLD increases the risk of progressing to more severe conditions such as metabolic dysfunction-associated steatohepatitis (MASH), which is marked by inflammation, ballooning, and potential fibrosis.
"); document.write("In response to the pressing need of effective treatments for these metabolic disorders, researchers led by Prof. Jin Hee Ahn from Gwangju Institute of Science and Technology (GIST) meticulously developed compound 11c, a novel peripheral 5HT2A antagonist. This research was made available online on January 20, 2024, and was published in Nature Communications, highlighting a significant therapeutic breakthrough. The compound showcased a promising profile and demonstrated efficacy in preclinical models, positioning it at the forefront of groundbreaking advancements in the field.
"); document.write("11c exhibits promising attributes, including robust biological activity and a favorable safety profile. Dr. Haushabhau Shivaji Pagire, first author and senior researcher at the Medicinal Chemistry Laboratory at GIST, emphasizes, \"Our meticulous analyses have revealed a significant reduction in inflammatory and fibrosis markers, attesting to the potent anti-inflammatory and fibrotic effect of the compound. This action, targeting both inflammation and fibrosis, is a promising step forward in treating MASH.\"